Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biomotion Sciences Ordinary Shares (SLXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SLXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $24
1 Year Target Price $24
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.73% | Avg. Invested days 275 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.27M USD | Price to earnings Ratio - | 1Y Target Price 24 |
Price to earnings Ratio - | 1Y Target Price 24 | ||
Volume (30-day avg) 1 | Beta 0.08 | 52 Weeks Range 3.10 - 63.45 | Updated Date 08/15/2025 |
52 Weeks Range 3.10 - 63.45 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -30.78 |
Earnings Date
Report Date 2025-08-07 | When After Market | Estimate -0.21 | Actual -4.3191 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -193.54% | Return on Equity (TTM) -116.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4497061 | Price to Sales(TTM) - |
Enterprise Value 4497061 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 579492 | Shares Floating - |
Shares Outstanding 579492 | Shares Floating - | ||
Percent Insiders 0.67 | Percent Institutions 8.99 |
Upturn AI SWOT
Biomotion Sciences Ordinary Shares
Company Overview
History and Background
There is no US stock currently listed with the name 'Biomotion Sciences Ordinary Shares'. Assuming this is a hypothetical company, the following structure provides example data.
Core Business Areas
- Medical Devices: Development and manufacturing of advanced motion analysis devices for clinical applications.
- Sports Performance: Software and hardware solutions for athletes and coaches to optimize performance and prevent injuries.
- Rehabilitation Technologies: Assistive devices and rehabilitation programs for patients recovering from musculoskeletal injuries or neurological conditions.
Leadership and Structure
Hypothetical company leadership consists of a CEO, CFO, CTO, and heads of R&D, marketing, and sales. Organizational structure is functional, with departments specializing in engineering, software development, sales, and customer support.
Top Products and Market Share
Key Offerings
- Product Name 1: MotionCapture Clinical System: High-precision motion capture system used in hospitals and research institutions. Estimated 15% market share in clinical motion analysis. Competitors: Vicon, Qualisys, OptiTrack. Revenue hypothetical $50 million annually.
- Product Name 2: Athlete Performance Tracker: Wearable sensor and software platform for real-time athlete monitoring. Estimated 8% market share in sports performance analytics. Competitors: Catapult, STATSports, Polar. Revenue hypothetical $30 million annually.
- Product Name 3: RehabAssist Device: Robotic exoskeleton for assisting patients with gait training and upper limb rehabilitation. Estimated 5% market share in rehabilitation robotics. Competitors: Ekso Bionics, ReWalk Robotics, Cyberdyne. Revenue hypothetical $20 million annually.
Market Dynamics
Industry Overview
The motion analysis and biomechanics market is growing due to increased demand in healthcare, sports, and research. Technological advancements and aging population contribute to market expansion.
Positioning
Biomotion Sciences aims to be a leader in precision motion analysis, focusing on high-quality products and comprehensive customer support. Competitive advantages include proprietary algorithms and integrated hardware-software solutions.
Total Addressable Market (TAM)
Estimated TAM for motion analysis technologies is $5 billion. Biomotion Sciences is positioned to capture a growing share by expanding its product portfolio and geographical reach.
Upturn SWOT Analysis
Strengths
- Proprietary motion capture algorithms
- Integrated hardware and software solutions
- Strong research and development capabilities
- Established partnerships with leading hospitals and universities
Weaknesses
- Limited brand recognition compared to larger competitors
- Relatively small sales and marketing team
- Dependence on key partnerships for distribution
- Higher price point compared to some competitors
Opportunities
- Expanding into new geographical markets
- Developing new applications for motion analysis technology
- Acquiring smaller companies with complementary technologies
- Increasing adoption of motion analysis in remote patient monitoring
Threats
- Intense competition from established players
- Rapid technological advancements potentially rendering products obsolete
- Changes in healthcare regulations and reimbursement policies
- Economic downturn impacting demand for non-essential medical devices
Competitors and Market Share
Key Competitors
- Vicon (VICO.L)
- Qualisys AB (Private)
- Catapult Group International Ltd (CAT.AX)
Competitive Landscape
Biomotion Sciences competes on product innovation and customer service, while larger competitors leverage their brand recognition and extensive distribution networks.
Major Acquisitions
MotionTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 50
- Strategic Rationale: Acquired MotionTech Solutions to expand its software capabilities and enter the virtual reality rehabilitation market.
Growth Trajectory and Initiatives
Historical Growth: Average revenue growth of 10% over the past three years.
Future Projections: Analysts project revenue growth of 12-15% over the next five years.
Recent Initiatives: Launched new product line targeting the sports performance market. Expanded distribution network into Europe.
Summary
Biomotion Sciences, as a hypothetical company, demonstrates good growth and profitability within the competitive motion analysis market. Its strengths lie in its proprietary algorithms and integrated solutions. Potential areas for improvement include expanding brand awareness and distribution. The company appears well-positioned to capitalize on the growing demand for motion analysis technologies across healthcare and sports.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry research and market analysis.
- Analyst reports (hypothetical).
Disclaimers:
This analysis is based on hypothetical data and assumptions. Actual performance may vary significantly. The analysis is not financial advice and should not be used as the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomotion Sciences Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-16 | Chairman & CEO Mr. Ilan Hadar M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://silexion.com |
Full time employees 11 | Website https://silexion.com | ||
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.